Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis

• Published in: Annals of general psychiatry 2017-02, Vol.16 (1), p.9-9, Article 9
• Main Authors: Correll, Christoph U, Ng-Mak, Daisy S, Stafkey-Mailey, Dana, Farrelly, Eileen, Rajagopalan, Krithika, Loebel, Antony
• Format: Article
• Language: English
• Subjects: Primary Research
• ISSN: 1744-859X; 1744-859X
• DOI: 10.1186/s12991-017-0133-7

Serious mental illnesses are associated with increased risk of cardiometabolic comorbidities. The objective of this study was to evaluate the prevalence of cardiometabolic comorbidity and its association with hospitalization outcomes and costs among inpatients with schizophrenia or bipolar disorder. This retrospective database analysis reviewed patients with an inpatient diagnosis of schizophrenia or bipolar disorder from the Premier Perspective® Database (4/1/2010-6/30/2012). Patients were categorized into 4 cohorts based on the number of ICD-9-CM cardiometabolic comorbidities (i.e., 0, 1, 2, or 3+). Outcomes included length of stay, mortality during the index hospitalization, healthcare costs, and 30-day all-cause readmission rates. Of 57,506 patients with schizophrenia, 66.1% had at least one cardiometabolic comorbidity; 39.3% had two or more comorbidities. Of 124,803 patients with bipolar disorder, 60.5% had at least one cardiometabolic comorbidity; 33.4% had two or more. Average length of stay was 8.5 (for patients with schizophrenia) and 5.2 (for patients with bipolar disorder) days. Each additional cardiometabolic comorbidity was associated with an increase in length of stay for patients with bipolar disorder (